Scarica l'app Stockscreener
86.15
0.17%
0.1918
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$85.96
Aprire:
$86.08
Volume 24 ore:
2.99M
Relative Volume:
0.61
Capitalizzazione di mercato:
$49.67B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
46.81
EPS:
1.8406
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+0.38%
1M Prestazione:
+6.02%
6M Prestazione:
-0.65%
1 anno Prestazione:
+10.78%
Intervallo 1D:
$85.83
$88.02
Intervallo di 1 settimana:
$85.52
$88.28
Portata 52W:
$72.30
$88.28
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.25 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
85.75 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.78 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
74.20 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Boston Scientific’s $1.5B bet signals heart valve market battle - Modern Healthcare News
Allstate Corp Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock By Investing.com - Investing.com Australia
Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock - Investing.com Australia
Edwards Lifesciences (EW) executive sells 23,145 shares at $86.42 average price - Stock Titan
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Donald Bobo reports multiple Common stock sales (EW) in Form 144 - Stock Titan
Edwards Lifesciences Has Everything Investors Want Except Value (NYSE:EW) - Seeking Alpha
Legal & General Group Plc Has $376.46 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences stock hits 52-week high at 87.89 USD - Investing.com
Swedbank AB Lowers Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences’ SWOT analysis: stock gains from rival’s setback By Investing.com - Investing.com Australia
Edwards Lifesciences’ SWOT analysis: stock gains from rival’s setback - Investing.com
Edwards Lifesciences Corp. (EW) Stock Analysis: Healthcare Giant with 13% Upside Potential - DirectorsTalk Interviews
Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Rathbones Group PLC - MarketBeat
ABN Amro Investment Solutions Raises Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell Alert: Daveen Chopra Sells Shares of Edwards Lifesc - GuruFocus
Analysts Offer Insights on Healthcare Companies: P3 Health Partners (PIII) and Edwards Lifesciences (EW) - The Globe and Mail
Edwards Lifesciences Corp (EW) Stock Up 3.1% and Still Undervalued -- GF Score: 95/100 - GuruFocus
Edwards Lifesciences (NYSE: EW) exec sells 1,500 common shares - Stock Titan
Edwards Lifesciences (EW) Form 144: Broker-listed proposed sale notice - Stock Titan
19,073 Shares in Edwards Lifesciences Corporation $EW Purchased by Fideuram Intesa Sanpaolo Private Banking S.P.A. - MarketBeat
Investment House LLC Trims Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
North Dakota State Investment Board Buys Shares of 19,728 Edwards Lifesciences Corporation $EW - MarketBeat
Handelsbanken Fonder AB Has $102.60 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences CVP Lippis sells $50,306 of common stock By Investing.com - Investing.com Nigeria
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Sells $50,306.80 in Stock - MarketBeat
Edwards Lifesciences CVP Lippis sells $50,306 of common stock - Investing.com India
Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M - TradingView
Edwards Lifesciences exec sells 620 shares after option exercise | EW Insider Trading - Stock Titan
Edwards Lifesciences (EW) CVP Donald Bobo Jr. sells 17,968 shares in open-market trades - Stock Titan
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences (NYSE: EW) Form 144 lists 150,758 units via broker - Stock Titan
Northwestern Mutual Wealth Management Co. Purchases 1,093,692 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
[144] Edwards Lifesciences Corp SEC Filing - Stock Titan
Edwards Lifesciences Corporation $EW Stock Position Boosted by Bank Julius Baer & Co. Ltd Zurich - MarketBeat
Top Edwards Lifesciences (EW) Competitors 2026 - MarketBeat
Are Wall Street Analysts Bullish on Edwards Lifesciences Stock? - Yahoo Finance
Scaling heart valve manufacturing to deliver life-saving treatments across Europe - Jacobs
VIRGINIA RETIREMENT SYSTEMS ET Al Trims Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
[Form 4] Edwards Lifesciences Corp Insider Trading Activity - Stock Titan
Edwards Lifesciences CEO Zovighian sells $2.83m in shares By Investing.com - Investing.com Nigeria
Edwards Lifesciences CEO Zovighian sells $2.83m in shares - Investing.com
Edwards Lifesciences (EW) CVP exercises 13,457 performance shares with 7,469 withheld for taxes - Stock Titan
Edwards Lifesciences (EW) executive vests performance units and withholds shares for taxes - Stock Titan
Edwards Lifesciences (NYSE: EW) lists vested RSUs and prior 22,430-share sale - Stock Titan
Edwards Lifesciences Corp at Bank of America Global Healthcare Conference Transcript - GuruFocus
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):